ALFA FinderNSE filing, NSE: BALAJIPHOS. Summary written from the filing by ALFA Finder's alert engine.
Balaji Phosphates Ltd: key numbers
- Share price
- ₹127.75
- Market cap
- ₹303.8 Cr
- Revenue (annual)
- ₹170.5 Cr
- Net profit (annual)
- ₹10.22 Cr
- P/E (TTM)
- 29.7×Sector 11.1×
- Promoter holding
- 69.90%
- FII holding
- 1.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaji Phosphates Ltd
All →Balaji Phosphates H1 FY27 Results: Net Profit ₹11.7 Cr, Up 46.2% YoY
Balaji Phosphates Ltd reported revenue from operations of ₹106.9 Cr (+26.2% YoY) and net profit of ₹11.7 Cr (+46.2% YoY) for H1 FY27.
- Key figure
- Net profit ₹11.7 Cr · +46.2% YoY
Balaji Phosphates Preferential Issue
Balaji Phosphates filed a revised valuation report for in-principle approval of its equity shares and convertible warrants issue. The filing responds to an NSE letter dated November 4, 2026, with no amount stated.
Balaji Phosphates Board Meeting Date
Balaji Phosphates has intimated a board meeting on 13-Nov-2026 to consider unaudited half-year results. No financial figures are disclosed in this advance notice.
Balaji Phosphates Other Announcement
Balaji Phosphates Limited has informed regarding the non-applicability of corporate governance provisions for the quarter ended 30th September, 2026, due to its SME listing status.
Balaji Phosphates Fund Raise of ₹23.45 Cr
Balaji Phosphates received shareholder approval to issue 25,00,000 convertible warrants worth ₹23.45 Crore and 14,49,900 equity shares for a business acquisition via preferential issue.
- Value
- ₹23.45 Cr
Balaji Phosphates Capital Structure Change
Balaji Phosphates' shareholders approved the issuance of 5,146,350 convertible warrants and 1,449,900 equity shares to promoters and other investors at the 30th AGM.
Other other announcement announcements
All →Religare Enterprises Other Announcement
Religare Enterprises filed CARE Ratings' monitoring agency report for the quarter ended September 30, 2026, on its Rs 1,500 crore preferential warrant issue. The report states proceeds were used per the offer document with no deviation.
Optivalue Tek Consulting Other Announcement
Optivalue Tek filed Acuité's half-yearly monitoring report on IPO proceeds for H1 FY2026-27. No deviation from the offer objects was observed.
5Paisa Capital Other Announcement
5paisa Capital Ltd filed its quarterly shareholding pattern under Regulation 31(1)(c). It reports routine holding figures with no new transaction or corporate event.
Chennai Meenakshi Multispeciality Hospital Other Announcement
Chennai Meenakshi Multispeciality Hospital issued a duplicate share certificate for 100 shares to Inder Chand Kothari L under folio 00008717. The intimation is routine share-certificate paperwork with no transaction or money involved.
Axel Polymers Other Announcement
Axel Polymers reports no deviation in utilisation of its Rs 11.18 Crore preferential issue proceeds for the quarter ended 30 September 2026. This is a routine Regulation 32 statement of deviation with a clean auditor certificate.
360 One Wam Other Announcement
360 ONE WAM disclosed PIT sales by five insiders on 12 November 2026, totalling about Rs 3.55 Crore. The sellers are designated persons, KMP and an employee's relative, with no promoter involved.
- Value
- ₹3.55 Cr